Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination

Vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy in preventing the onset of disease. However, the immune response to infection immediately after the first vaccination remains unknown. We examined the anti-SARS-CoV-2-binding-antibody titers and neutra...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumura, Nobumasa, Saito, Sho, Takamatsu, Yuki, Takeuchi, Junko S., Asai, Yusuke, Sanada, Mio, Iwamoto, Noriko, Maeda, Kenji, Mitsuya, Hiroaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444155/
https://www.ncbi.nlm.nih.gov/pubmed/36067912
http://dx.doi.org/10.1016/j.jiac.2022.08.026
Descripción
Sumario:Vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy in preventing the onset of disease. However, the immune response to infection immediately after the first vaccination remains unknown. We examined the anti-SARS-CoV-2-binding-antibody titers and neutralizing activity in patients who developed coronavirus disease 2019 after the first vaccination. The amount of anti-SARS-CoV-2-binding antibodies and neutralizing activity drastically increased from the first to the second collection. Our results may provide important data on the course of immune response following vaccination.

Ejemplares similares